Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
Ronnie AronsonJuan Pablo FriasAllison GoldmanAmanda DarekarBrett LauringSteven G TerraPublished in: Diabetes, obesity & metabolism (2018)
Ertugliflozin treatment over 52 weeks improved glycaemic control and reduced body weight and SBP, but increased GMIs.